Noven Pharmaceuticals 3Q earnings top expectations, revenue misses |
|
|
|
Published
:
Thu, 08 Nov 2007 15:03
|
BOSTON (Thomson Financial) - Noven Pharmaceuticals Inc. Thursday reported third-quarter adjusted net income of $7.6 million, or 30 cents a share, up from $5 million, or 20 cents a share, a year agoThe mean estimate of analysts polled by Thomson Financial was for 17 cents a share.Revenue rose 39% to $21.8 million from $15.7 million a year ago, compared with analyst forecasts of $23.5 million.The company said the increase in revenue reflects the recognition of $3.3 million associated with sales of JDS's Pexeva and Lithobid products, higher sales of Noven's Vivelle-Dot estrogen patch and higher license revenues.The Miami-based women's health pharmaceutical company closed at $13.52.Michael Lauengerml/tk1COPYRIGHTCopyright Thomson Financial News Limited 2007. All rights reserved.The copying, republication or redistribution of Thomson Financial News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Financial News.
|
|
|
|
|
|
|
| Stock
Quotes * |
|
NASDAQ
|
|
2251.69 |
-12.87 (
-0.56 %)
|
| SYMBOL (
2010-07-29 ) |
| LAST |
CHANGE
|
|
KAZAKHMYS
(
11:37am )
|
|
1220.00 |
+23.00 (
1.91 %)
|
|
LONMIN
(
11:35am )
|
|
1580.00 |
+21.00 (
1.35 %)
|
|
SHIRE
(
11:35am )
|
|
1490.00 |
+21.00 (
1.43 %)
|
| SYMBOL (
2010-07-29 )
|
| LAST |
CHANGE
|
|
DUPONT
(
4:00pm ) |
|
40.51 |
+0.24 (
0.59 %)
|
| SYMBOL (
2010-07-29 )
|
| LAST |
CHANGE
|
|
|
Print this Story
Noven Pharma: FDA issues approvable letter for Stavzor 